[STRATEGIC] Cancer Diagnostics ·
MedTech · Liquid Biopsy —
Announced Nov 19, 2025 — CLOSED March 23, 2026
Abbott Closes $23B Acquisition of Exact
Sciences, Entering the $60B Cancer Screening Market
The Abbott-Exact Sciences combination is the largest diagnostics
deal ever: by acquiring Cologuard — the world's leading at-home colorectal
cancer screening test — and Cancerguard's multi-cancer early detection blood
test, Abbott adds a $3B-plus revenue vertical with high-teens organic growth,
vaulting its total diagnostics sales above $12B annually.
DEAL SNAPSHOT
|
TOTAL EQUITY VALUE ~$21 Billion |
ANNOUNCED November 19, 2025 |
|
ENTERPRISE VALUE (INCL. NET DEBT) ~$23 Billion |
CLOSED March 23, 2026 |
|
PRICE PER SHARE $105.00 (all-cash) |
SHAREHOLDER APPROVAL 67.56% of eligible
shares voted in favour |
THE PARTIES
|
ACQUIRER Abbott Laboratories (NYSE:
ABT) North Chicago,
IL-based global healthcare company. CEO Robert Ford. FY2025 revenues ~$22B
across four segments: MedTech, Diagnostics, Nutrition, and Established
Pharmaceuticals. Abbott has described its strategy as a pivot toward
"personalized and preventative healthcare." To fund the $23B
enterprise value, Abbott executed a $20B senior notes offering in early March
2026 — one of the largest debt capital market transactions in healthcare
history. |
TARGET Exact Sciences Corporation
(Nasdaq: EXAS) Madison,
WI-based precision oncology company. CEO Kevin Conroy (remains in advisory
role post-close). FY2025 revenues ~$3B. Core products: Cologuard (stool DNA
test for colorectal cancer screening — FDA approved, #1 non-invasive CRC
screening in the U.S.); Oncotype DX (gene expression tests for breast and
prostate cancer treatment decisions); Cancerguard (a multi-cancer early
detection blood test). ~7,000 employees. |
DEAL OVERVIEW & FINANCING
Abbott agreed to
acquire all outstanding shares of Exact Sciences at $105.00 per share in cash
on November 19, 2025 — a 14% premium to Exact Sciences' closing price the prior
day. The total equity value of approximately $21 billion, combined with the assumption
of approximately $1.8 billion in net debt, produces an enterprise value of
approximately $23 billion.
The transaction
closed on March 23, 2026, after receiving all required regulatory clearances
(the last clearance was received on March 19, 2026) and shareholder approval
(67.56% of eligible shares voted in favor). To finance the acquisition, Abbott
completed a landmark $20 billion senior notes offering in early March —
absorbing the debt into an investment-grade capital structure supported by
Abbott's ~$22B revenue base.
Exact Sciences
will maintain its headquarters in Madison, Wisconsin. CEO Kevin Conroy
transitions to an advisory role to support integration and accelerate global
impact.
"Exact Sciences' innovation, its strong brand and
customer-focused execution are unrivalled in the cancer diagnostics space.
Together we will enter and lead in one of the fastest-growing segments in
healthcare."
— Robert Ford,
Chairman & CEO, Abbott
THE $60 BILLION PRIZE: CANCER SCREENING AND
PRECISION ONCOLOGY
The U.S. cancer
screening and precision oncology diagnostics market is estimated at $60 billion
— large, underpenetrated, and growing at double-digit rates driven by aging
demographics, expanding screening guidelines, and rising public awareness of
early detection's survival benefits. Cologuard alone achieved more than $2.5
billion in U.S. revenues in 2025, growing at high-teens rates. Cancerguard,
Exact Sciences' blood-based multi-cancer early detection test, targets a market
segment that currently does not exist at commercial scale — and that Abbott
believes will expand to tens of millions of annual tests within a decade.
Abbott brings to
the combination: a global commercial infrastructure (160+ countries),
regulatory expertise across multiple healthcare segments, and diagnostic
laboratory relationships spanning clinical chemistry, immunoassay, and
molecular diagnostics. Exact Sciences brings brand recognition, established
payer coverage (Cologuard is covered by Medicare and most commercial insurers),
and a growing clinical evidence base. Abbott projects approximately $100
million in annual synergies post-integration.
ADVISORS
Buy-side
Financial (Abbott): Morgan Stanley
& Co. LLC (exclusive; also provided fully committed debt financing)
Buy-side
Legal (Abbott): Wachtell, Lipton,
Rosen & Katz LLP
Sell-side
Financial (Exact Sciences): Centerview
Partners LLC (lead, also provided fairness opinion) + XMS Capital Partners LLC
Sell-side
Legal (Exact Sciences): Skadden,
Arps, Slate, Meagher & Flom LLP
Transfer
Agent (Exact Sciences): Equiniti
Trust Company LLC